Epogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson & Johnson) Drug Analysis 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: Epogen" drug pipelines has been added to ResearchAndMarkets.com's offering.

Epogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson & Johnson) is an erythropoiesis-stimulating agent administered by intravenous or subcutaneous injection, and is indicated for the treatment of anemia in chronic kidney disease and chemotherapy-induced anemia. The drug consists of recombinant human erythropoietin and targets the erythropoietin receptor, initiating the same pathway as native erythropoietin and triggering increased blood production in bone marrow.

Key Topics Covered:

List of Figures

Figure 1: Epogen for anemia in chronic kidney disease - SWOT analysis

Figure 2: Drug assessment summary of Epogen for anemia in chronic kidney disease

Figure 3: Drug assessment summary of Epogen for anemia in chronic kidney disease

Figure 4: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24

Figure 5: Epogen for chemotherapy-induced anemia - SWOT analysis

Figure 6: Drug assessment summary of Epogen in chemotherapy-induced anemia

Figure 7: Drug assessment summary of Epogen in chemotherapy-induced anemia

List of Tables

Table 1: Epogen drug profile

Table 2: Epogen pivotal trial data in anemia in chronic kidney disease

Table 3: Epogen other late-phase trial data in anemia in chronic kidney disease

Table 4: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24

Table 5: Epogen drug profile

Table 6: Epogen pivotal trial data in chemotherapy-induced anemia

Table 7: Epogen ongoing late-phase clinical trial in chemotherapy-induced anemia

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jn5hnv/epogen_epoetin?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs